Cutaneous Side Effects of Checkpoint Inhibitor Therapy

Overview / Definition Checkpoint inhibitors, including monoclonal antibodies targeting CTLA-4 (e.g., ipilimumab) and PD-1 or PD-L1 (e.g., pembrolizumab, nivolumab), are used in the treatment of various malignancies by enhancing T-cell activity. While effective in controlling tumor growth, these agents can induce a spectrum of immune-related adverse events, particularly affecting the skin. Epidemiology Skin toxicities associated with checkpoint inhibitors are common and may occur in up to 30%-40% of patients undergoing treatment. The incidence varies based on the specific agent used, the combination of therapies, and the underlying malignancy. Ipilimumab: 40% incidence of rash Pembrolizumab: 30% incidence of pruritus Nivolumab: 10-20% incidence of dermatitis Pathophysiology / Mechanism The cutaneous side effects of checkpoint inhibitors result from enhanced immune activation. The blockade of immune checkpoints leads to increased T-cell responses not only against the tumor but also against normal tissues, including the skin. This autoimmune reaction is mediated by T-helper 1 and T-helper 17 cells, which release pro-inflammatory cytokines. Activation of CD8+ T-cells targeting skin antigens Release of cytokines such as TNF-alpha and IL-17 Increased autoimmunity in predisposed individuals Clinical Presentation Cutaneous side effects can manifest in various forms: Rash: Morbilliform or maculopapular eruptions, often pruritic. Pruritus: Can be severe and debilitating. Vitiligo: Often seen in patients with melanoma, indicating an immune response. Psoriasiform dermatitis: Scaly plaques resembling psoriasis. Other manifestations: Erythema multiforme, lichenoid drug eruptions, and in rare cases, Stevens-Johnson syndrome. Diagnosis / Workup Diagnosis is primarily clinical, based on the timing and characteristics of the rash in relation to checkpoint inhibitor therapy. Key steps in the workup include: Detailed history including onset, duration, and nature of lesions. Physical ex